Selegiline in the treatment of sexual dysfunction in schizophrenic patients maintained on neuroleptics: A pilot study

Research output: Contribution to journalArticlepeer-review

Abstract

A double-blind, placebo-controlled crossover study was undertaken in 10 neuroleptic-treated male schizophrenic outpatients to assess the effect of coadministration of selegiline 15 mg/day for 3 weeks on their sexual dysfunction. Selegiline was not found to be effective in improving any domain of sexual functioning despite a significant decrease in prolactin levels (P < 0.05). This study emphasizes the complex nature of sexual dysfunction in schizophrenic-treated patients and the need for placebo-controlled trials for this condition.

Original languageEnglish
Pages (from-to)193-195
Number of pages3
JournalClinical Neuropharmacology
Volume26
Issue number4
DOIs
StatePublished - Jul 2003
Externally publishedYes

Keywords

  • Antipsychotics
  • Dopamine
  • L-deprenyl
  • Neuroleptics
  • Schizophrenia
  • Selegiline
  • Sexual dysfunction

Fingerprint

Dive into the research topics of 'Selegiline in the treatment of sexual dysfunction in schizophrenic patients maintained on neuroleptics: A pilot study'. Together they form a unique fingerprint.

Cite this